Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: Evaluation of drug clinical efficacy

Silvia A. Mandel, Micaela Morelli, Ilan Halperin, Amos D. Korczyn

Research output: Contribution to journalReview articlepeer-review

Abstract

Neurodegenerative diseases like Parkinson's disease (PD) and Alzheimer's disease (AD) are considered disorders of multifactorial origin, inevitably progressive and having a long preclinical period. Therefore, the availability of biological markers or biomarkers (BMs) for early disease diagnosis will impact the management of AD and PD in several dimensions; it will 1) help to capture high-risk individuals before symptoms develop, a stage where prevention efforts might be expected to have their greatest impact; 2) provide a measure of disease progression that can be evaluated objectively, while clinical measures are much less accurate; 3) help to discriminate between true AD or PD and other causes of a similar clinical syndrome; 4) delineate pathophysiological processes responsible for the disease; 5) determine the clinical efficacy of novel, disease-modifying (neuroprotective) strategies. In the long run the availability of reliable BMs will significantly advance the research and therapeutics of AD and PD.

Original languageEnglish
Pages (from-to)273-292
Number of pages20
JournalEPMA Journal
Volume1
Issue number2
DOIs
StatePublished - Jun 2010

Keywords

  • Alzheimer's disease
  • Apolipoprotein E
  • Biomarker
  • Disease modifying therapy
  • Neuroimaging
  • Parkinson's disease

Fingerprint

Dive into the research topics of 'Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: Evaluation of drug clinical efficacy'. Together they form a unique fingerprint.

Cite this